LLY Eli Lilly and Co

76.76
0  0%
Previous Close 0.00
Open 0.00
Price To book 0.00
Market Cap
Shares 0
Volume 0
Short Ratio 0.00
Av. Daily Volume 0

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2H 2017. LLY buyout of CLCD due 1Q 2017.
Lasmiditan - SPARTAN
Migraine
Phase 3 trial to be initiated in 2017.
Ultra rapid insulin
Diabetes
Phase 3 ongoing.
Tanezumab
Chronic low back pain
Phase 3 ongoing.
Tanezumab
Cancer pain
Phase 3 ongoing.
Tanezumab
Osteoarthritis
Phase 3 initiated August 2016. Announced in January 31 earnings call that trial has been terminated - see transcript link here for details.
Solanezumab
Prodromal Alzheimer's disease
Phase 3 ongoing.
Solanezumab
Preclinical Alzheimer's disease
Phase 3 initial PFS data due 1H 2017 with OS data due 2018.
Ramucirumab - RAINFALL
First-line gastric cancer
Phase 3 PFS data due 2017.
Ramucirumab
Second-line bladder cancer
Phase 3 ongoing. Data due 2017.
Flortaucipir F 18 (Tau imaging agent)
Alzheimer's disease
Phase 3 trial to be initiated in 2017.
Empagliflozin
Heart failure with preserved ejection fraction (HFpEF)
Phase 3 trial to be initiated in 2017.
Empagliflozin
Heart failure with reduced ejection fraction (HFrEF)
Phase 3 trial to be initiated in 2017.
Baricitinib
Psoriatic Arthritis
Phase 3 data due 2019.
AZD3293
Early Alzheimer's disease
Phase 3 data due late 2017.
Abemaciclib - MONARCH 3
HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC)
Phase 3 data due late 2017.
Alimta + Keytruda (MK-3475-189/KEYNOTE-189)
First-Line Non-Squamous Non-Small Cell Lung Cancer
Phase 3 data released March 20, 2017 - PFS primary endpoint met.
Abemaciclib - MONARCH 2
Second-line hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer
Phase 2 data released June 2016.
Abemaciclib - MONARCH 1
HR+, HER2- breast cancer
Phase 3 ongoing. Data due 2017.
Abemaciclib - JUNIPER
Thrid line KRAS mutation positive Non-small cell lung cancer (NSCLC)
Announced January 19 2016 that NDA Filing had been submitted. Three month delay announced January 13, 2017. CRL received April 14, 2017.
Baricitinib
Rheumatoid arthritis
BLA filing due 1H 2017.
Taltz
Psoriatic Arthritis

Latest News

  1. What to own ahead of earnings' busiest week
  2. Cramer's game plan: Here's what to own ahead of the busiest week of earnings
  3. Eli Lilly’s Estimate for Strattera, Other Neuroscience Products
  4. How Will Eli Lilly’s Alimta and Other Oncology Products Perform?
  5. Eli Lilly’s 1Q17 Estimates for Humalog, Other Endocrine Products
  6. Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL
  7. Will New Products Help Eli Lilly in 1Q17?
  8. This $26 Billion Company Is the Market's Most Overpriced Biotech Stock
  9. Growth Expected for Eli Lilly’s 1Q17 Revenue
  10. Lilly to Present Data for Galcanezumab for the Prevention of Migraine at the American Academy of Neurology (AAN) Annual Meeting
  11. Analyst Estimates for Eli Lilly’s 1Q17 Earnings
  12. Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
  13. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Eli Lilly and Company (LLY)
  14. Cramer Remix: Thanks to Apple & Samsung, this group just ...
  15. Cramer Remix: Thanks to Apple and Samsung, this group just got its mojo back
  16. Eli Lilly & Co. – Value Analysis (NYSE:LLY) : April 19, 2017
  17. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eli Lilly and Company - LLY
  18. Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed
  19. Could Lilly Outperform These Bigger Rivals On Strong Diabetes Meds?
  20. FDA Rejects Eli Lilly, Incyte's Commercialization Application